First leukaemia patient in NSW treated with CAR-T immunotherapy
The first commercial release and administration of Kymriah CAR-T immunotherapy occurred today at Cell & Molecular Therapies (CMT), Royal Prince Alfred Hospital. Professor Rasko who heads CMT said "We hope our patient with leukaemia benefits from this CAR-T product in coming weeks, which represents many years of sustained effort by many people”.
